Benzinga | May 10, 2021 09:18AM EDT

Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $56

Morgan Stanley maintains Insmed (NASDAQ:INSM) with a Overweight and lowers the price target from $58 to $56.